Alemtuzumab yields positive result in Puerto Rican woman with multiple sclerosis

This study highlights the importance of investigating the subtypes of Multiple Sclerosis with respect to definitions, diagnosis and treatment.

Dr. Ángel Chinea, neurologist, medical director of the Multiple Sclerosis Foundation. Photo: Journal of Medicine and Public Health, Fabiola Plaza.

This time it is a case where a 41-year-old woman, diagnosed with Multiple sclerosis in 2001 (at age 21) and currently treatment with alemtuzumabwhich was presented at the Center for Multiple sclerosis of San Juan in February 2021 for an active follow-up evaluation of outbreaks and referrals.

On examination, the patient was found to have bilateral lower extremity weakness with wheelchair assistance, neurogenic bladder, constipation, gait impairment, loss of coordination, and mild cognitive impairment.

“At the present visit, the patient was alert and oriented to space, time, and person. Medical history included a diagnosis of Multiple sclerosis relapsing-remitting and one cesarean section. In addition, the patient experienced an aggressive VZV infection at age 12, leading to her hospitalization. Her family history included Multiple sclerosis in a cousin, a third degree relative, on the mother’s side”, indicate the authors of the case.

They noted that the disease-modifying therapies for this patient changed several times over the years. In 2001, interferon beta 1-b was started for seven years, until 2008, when it was changed to natalizumab. He continued on natalizumab for three years, switching to glatiramer acetate in 2011 and then dimethyl fumarate in 2013.

body-image

Alemtuzumab treatment has significantly improved this patient’s cognitive abilities, motor control, and overall quality of life. Photo: Pharmaceutical.

“At that time, the patient had more than three relapses in less than 2 years, prompting one last change. The first dose of alemtuzumab it was administered in October 2016, the second dose in October/2017 and the third dose in May/2019″, details the case.

They added that treatment with alemtuzumab It has significantly improved this patient’s cognitive abilities, motor control, and overall quality of life.

case relevance

Specialists explain that patients with Multiple sclerosisvery active relapsing-remitting, have limited treatment options and it is necessary to study the efficacy for recovery from deterioration in these patients.

“The discussion of this case allows us to know the beneficial results of alemtuzumab in patients with Multiple sclerosis highly active relapsing-remitting. Supports previous findings of disease stabilization after treatment with alemtuzumab of the Multiple sclerosis highly active. It also serves as evidence of clinical improvement and decrease in progression after following the proposed treatment for the Multiple sclerosis highly active or aggressive,” they report.

In addition, they concluded that this case serves as educational information about the therapeutic benefits of alemtuzumab in patients with Multiple sclerosis recurring-sender.

“Specifically, this drug seems beneficial for those patients with Multiple sclerosis very active who have not been able to improve or control their disease with DMT. Reporting of these findings allows analysis of alemtuzumab as an effective treatment for patients with Multiple sclerosis very active or aggressive. Overall, this study highlights the importance of investigating the subtypes of Multiple sclerosis regarding definitions, diagnosis and treatment,” they concluded.

The multiple sclerosis (MS) is a debilitating autoimmune disease that currently affects around 2.8 million people worldwide. It is estimated that 2,387 of them live on the island of Puerto Rico.

Access the case here.

Leave a Reply

Your email address will not be published.

Back to top button

Adblock Detected

Please consider supporting us by disabling your ad blocker